hotspot -WSS

hotspot

author：explore 2025-09-28 02:30:22 - browse：11

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Readout LOUD podcast: What to know about H5N1 bird flu

entertainment

WSS

Medicare solvency divides Republicans at the presidential debate

The new shift in health care is toward less care

The new shift in health care is toward less care

H5N1 bird flu: what we're starting to learn about infection in cows

Diversify hospital leadership teams to protect BIPOC patient health

Researchers on aging grapple with how to calculate biological age

explore

hotspot

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Extreme heat events are a public health emergency

Guidelines to prevent youth baseball injuries need more muscle

After gene therapy, two congenitally deaf children hear for the first time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

First recipient of genetically engineered pig kidney has died

Walensky prepares to leave CDC — and Congress — behind

H5N1 communication has been strictly for the birds

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Victims of gun violence feel impacts long after bullet wound

entertainment

Senate panel clears PBM, hopsital reforms

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

How to improve immunocompromised access to mAb treatments

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

FDA approves Recor Medical high blood pressure device

Wikipedia

entertainment

entertainment

hotspot